140 related articles for article (PubMed ID: 16301829)
1. Introduction. Critical role of anti-angiogenesis and VEGF inhibition in colorectal cancer.
Díaz-Rubio E; Schmoll HJ
Oncology; 2005; 69 Suppl 3():1-3. PubMed ID: 16301829
[No Abstract] [Full Text] [Related]
2. The role of new agents in the treatment of colorectal cancer.
Ruiz de Erenchun F
Oncology; 2005; 68(2-3):162; author reply 162. PubMed ID: 16097096
[No Abstract] [Full Text] [Related]
3. [New medications; bevacizumab].
Cohen AF; van Bronswijk H
Ned Tijdschr Geneeskd; 2006 Oct; 150(40):2194-5. PubMed ID: 17061430
[TBL] [Abstract][Full Text] [Related]
4. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer.
Ferrara N; Hillan KJ; Gerber HP; Novotny W
Nat Rev Drug Discov; 2004 May; 3(5):391-400. PubMed ID: 15136787
[No Abstract] [Full Text] [Related]
5. Targeting vascular endothelial growth factor and angiogenesis for the treatment of colorectal cancer.
Collins TS; Hurwitz HI
Semin Oncol; 2005 Feb; 32(1):61-8. PubMed ID: 15726507
[TBL] [Abstract][Full Text] [Related]
6. Antiangiogenic drugs currently used for colorectal cancer: what other pathways can we target to prolong responses?
Abbadessa G; Vogiatzi P; Rimassa L; Claudio PP
Drug News Perspect; 2007 Jun; 20(5):307-13. PubMed ID: 17878958
[TBL] [Abstract][Full Text] [Related]
7. [PZ Innovation Prize for Avastin: Bevacizumab--new therapy option in colon carcinoma].
Krankenpfl J; 2005; 43(7-10):234. PubMed ID: 16515304
[No Abstract] [Full Text] [Related]
8. The horizon of antiangiogenic therapy for colorectal cancer.
Olszewski AJ; Grossbard ML; Kozuch PS
Oncology (Williston Park); 2005 Mar; 19(3):297-306; discussion 306, 308, 317-33. PubMed ID: 15828549
[TBL] [Abstract][Full Text] [Related]
9. [Therapeutic strategies using VEGF inhibitors in colorectal cancer].
Boige V; Malka D; Ducreux M
Bull Cancer; 2005 Aug; 92(Spec no):S29-36. PubMed ID: 16387667
[TBL] [Abstract][Full Text] [Related]
10. Bevacizumab: one treatment for all the seasons?
Gelibter AJ; Di Segni S; Zeuli M; Cognetti F
J Clin Oncol; 2008 Jan; 26(3):511; author reply 511-2. PubMed ID: 18202430
[No Abstract] [Full Text] [Related]
11. Antiangiogenesis agents in colorectal cancer.
Hubbard J; Grothey A
Curr Opin Oncol; 2010 Jul; 22(4):374-80. PubMed ID: 20375894
[TBL] [Abstract][Full Text] [Related]
12. Bevacizumab beyond progression: does this make sense?
Ellis LM; Haller DG
J Clin Oncol; 2008 Nov; 26(33):5313-5. PubMed ID: 18854567
[No Abstract] [Full Text] [Related]
13. Anti-VEGF therapy: a new approach to colorectal cancer therapy.
Carrato A; Gallego-Plazas J; Guillen-Ponce C
Expert Rev Anticancer Ther; 2006 Oct; 6(10):1385-96. PubMed ID: 17069524
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of action of bevacizumab as a component of therapy for metastatic colorectal cancer.
Ellis LM
Semin Oncol; 2006 Oct; 33(5 Suppl 10):S1-7. PubMed ID: 17145519
[TBL] [Abstract][Full Text] [Related]
15. [Role of angiogenesis inhibitors in the treatment of colorectal cancer].
Bodoky G
Magy Onkol; 2007; 51(2):139-44. PubMed ID: 17660870
[TBL] [Abstract][Full Text] [Related]
16. [Anti-angiogenic treatment and colorectal cancer].
André T; Tournigand C; Abbas F; Louvet C; de Gramont A;
Bull Cancer; 2007 Jul; 94 Spec No():S211-9. PubMed ID: 17846007
[TBL] [Abstract][Full Text] [Related]
17. Angiogenesis inhibitors in the treatment of colorectal cancer.
Iqbal S; Lenz HJ
Semin Oncol; 2004 Dec; 31(6 Suppl 17):10-6. PubMed ID: 15696025
[TBL] [Abstract][Full Text] [Related]
18. Anti-angiogenic treatment of gastrointestinal malignancies.
Salmon JS; Lockhart AC; Berlin J
Cancer Invest; 2005; 23(8):712-26. PubMed ID: 16377590
[TBL] [Abstract][Full Text] [Related]
19. VEGF release by MMP-9 mediated heparan sulphate cleavage induces colorectal cancer angiogenesis.
Hawinkels LJ; Zuidwijk K; Verspaget HW; de Jonge-Muller ES; van Duijn W; Ferreira V; Fontijn RD; David G; Hommes DW; Lamers CB; Sier CF
Eur J Cancer; 2008 Sep; 44(13):1904-13. PubMed ID: 18691882
[TBL] [Abstract][Full Text] [Related]
20. Future directions in vascular endothelial growth factor-targeted therapy for metastatic colorectal cancer.
Grothey A
Semin Oncol; 2006 Oct; 33(5 Suppl 10):S41-9. PubMed ID: 17145524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
